Sermorelin
Human observationalWADA prohibitedAlso known as: GHRH (1-29)
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A GHRH analogue with decades of clinical history — first as a diagnostic for GH deficiency, now widely prescribed through longevity and wellness clinics. Its GH-releasing effect in humans is well documented; modern anti-ageing outcome data are thinner.
Mechanism
Stimulates pituitary growth-hormone secretion as a GHRH analogue, preserving the body's natural pulsatile release pattern.
Evidence
Real human clinical history and documented GH release; formal outcome trials for today's anti-ageing use are limited.
Community-reported information
Prescription/compounded contexts vary. Anecdotal outside those; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
~10–20 minutes.
Storage
Refrigerate.
Commonly reported side effects
- Flushing
- Injection-site reactions
- Headache
Legal status by region
- USHistorically available; compounding status has changed — verify current status.
Legal status changes over time; verify locally before relying on this.
Frequently asked questions
- What was sermorelin originally used for?
- It began as a diagnostic agent for growth-hormone deficiency, which is why it has more human clinical history than most peptides in this category. Today it is mainly prescribed through longevity clinics for GH support.
- Is sermorelin banned in sport?
- Yes — GHRH analogues including sermorelin are on the WADA prohibited list.